Table 4 Association between immune-related adverse events (irAEs) by pembrolizumab and combined positive scoring (CPS) in our department
CPS < 1 | 1 ≤ CPS < 20 | 20 ≤ CPS | |
|---|---|---|---|
Number of irAE cases/number of patients administered pembrolizumab | 0/5 | 0/8 | 4/20 |
Incidence of irAEs | 0% | 0% | 20% |